Developing a new treatment for ovarian and kidney cancers using CAR T-cell therapy.
Official title: Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas
Funded at Celdara Medical, LLC · NIH-10696145 · Data updated 2026-11-12
This study is testing a new treatment called CM-CX1 that uses your own immune cells to help fight ovarian clear cell and renal cell cancers, aiming to make the treatment more effective than what’s currently available.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Celdara Medical, LLC NIH-funded |
| Lab location | 1 site (Lebanon, United States) |
| Project start | September 8, 2021 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $769,404 |
| NIH project number | 5R44CA265424-03 |
| Project ID | NIH-10696145 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with ovarian clear cell carcinoma or renal cell carcinoma who may benefit from innovative immunotherapy approaches.
✕Less likely to help
Patients with cancers that do not express the TIM-1 marker or those who are not eligible for CAR T-cell therapy may not benefit from this research.
What this research studies
This research focuses on creating a novel CAR T-cell therapy called CM-CX1, which aims to treat ovarian clear cell and renal cell carcinomas. The approach involves genetically modifying a patient's own T cells to target a specific marker found in these cancers, enhancing the immune system's ability to fight the disease. By utilizing the body's natural defenses, this therapy seeks to provide a more effective treatment option compared to traditional methods. The research is currently in the preclinical phase, preparing for human trials.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment option for patients with ovarian and renal cancers, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promise in using CAR T-cell therapy for various cancers, indicating a potential for success with this novel approach.
Where this research is happening
-
Celdara Medical, LLC
Lebanon, United States Active
Researchers
- Principal investigator: Murad, Joana M — Celdara Medical, LLC
- Study coordinator: Murad, Joana M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.